Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Stock Information for Oncternal Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.